SAN DIEGO, Sept. 25, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) ( http://www.apricusbio.com ) announced today that Bassam Damaj, Ph.D., President and Chief Executive Officer, will present at the Sachs 2012 Biotech in Europe Investor Forum, being held at the Hilton Zurich Airport Hotel, Switzerland. Apricus Biosciences' presentation will take place on Monday, October 1 st at 9:00 a.m. Central European Time. Dr. Damaj will be giving a corporate update on the Company's licensing efforts including its recent Vitaros® licensing transaction with Takeda for the United Kingdom and the ongoing efforts for the rest of Europe and Latin America, as well as a regulatory status update for MycoVa™ and Femprox®. About Apricus Biosciences, Inc. Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, high-demand therapeutic classes. The Company has four approved products and has developed a strong pipeline of multiple late-stage product opportunities. With commercial operations in both the U.S. and Europe (France), Apricus Bio generates revenues and growth from sales of its commercial products and by out-licensing, in certain territories, its pipeline products and NexACT® technology. Apricus Bio's growth strategy is to acquire, develop, and commercialize new products through strategic partnerships. The Company currently has commercial partnerships with multiple large pharmaceutical companies including Novartis, Abbot Laboratories, Takeda, Sandoz, Warner Chilcott and Bracco, and co-promotes multiple products in France. Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the NASDAQ under the ticker symbol APRI. For further information on Apricus Bio, visit http://www.apricusbio.com , and for information on its subsidiary please visit http://www.nexmedusa.com . You can also receive information at http://twitter.com/apricusbio . Apricus Bio's Forward-Looking Statement Safe Harbor Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to further develop its products and product candidates, to have its products and product candidates such as Femprox ® and MycoVa™ receive patent protection and be approved by relevant regulatory authorities, to successfully commercialize such products as Vitaros®, Femprox®, MycoVa™, Totect ® , Granisol ® , Aquoral™ and NitroMist™ and NexACT ® product candidates and drug delivery technology and to achieve its development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
CONTACT: Apricus Bio Investor Relations: David Pitts Argot Partners 212-600-1902 email@example.com